SCHAUMBURG -- Sagent Pharmaceuticals announced the launch of Doxorubicin Hydrochloride Injection, USP, an antineoplastic agent, in three vial presentations.
oxorubicin Hydrochloride Injection has been used successfully to produce regression in disseminated neoplastic conditions such as acute lymphoblastic leukemia, acute myeloblastic leukemia,
 According to IMS, for the 12 months ending September 2013, the U.S. market for Doxorubicin Hydrochloride Injection, USP approximated $14 million.
As with all products in Sagent's portfolio, Doxorubicin features Sagent's PreventIV Measures packaging and labeling, designed to help reduce medication errors.